Until recently, a chronic lymphocytic leukemia (CLL) diagnosis came with limited options and a lot of uncertainty. Today, long-term results show how much treatment has changed — and what patients and ...

The rapid development of novel agents and combinations in chronic lymphocytic leukemia/small lymphocytic lymphoma has led to multiple options for frontline therapy and relapse, including continuous ...

This tutorial will teach you how to download, install and run a series of biological problems in PhysiCell. Please note that this tutorial will be periodically ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and Richter’s strategies. In this episode of Treating Together, host Marc ...

Eli Lilly has chalked up another victory in the chronic lymphocytic leukemia (CLL) space, as its BTK inhibitor Jaypirca delivered its fourth positive phase 3 readout in the blood cancer. Monday, Lilly ...

Please provide your email address to receive an email when new articles are posted on . The combination is the first all-oral, fixed duration treatment for patients with CLL and or small lymphocytic ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States. A study appearing in Clinical Cancer ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...